Reducing racial disparities in liver cancer outcomes
Official title: Elimination Racial Disparities in Hepatocellular Carcinoma
Funded at Glax, LLC · NIH-11061303 · Data updated 2026-11-12
This study is looking at how a special molecule called SATB2 inhibitor might help improve treatment for African Americans with liver cancer, by exploring how different factors like environment and genetics affect the disease.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Glax, LLC NIH-funded |
| Lab location | 1 site (Wilmington, United States) |
| Project start | March 26, 2024 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $978,037 |
| NIH project number | 5R44MD019234-02 |
| Project ID | NIH-11061303 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are African American individuals diagnosed with hepatocellular carcinoma.
✕Less likely to help
Patients who do not have hepatocellular carcinoma or are not of African American descent may not benefit from this research.
What this research studies
This research focuses on addressing the higher rates of hepatocellular carcinoma (HCC) among African Americans by investigating a patented molecule known as SATB2 inhibitor. The study aims to understand how environmental, economic, and genetic factors contribute to the development and progression of HCC in this population. By utilizing advanced methodologies, including in vitro and in vivo testing, the research seeks to identify effective treatments that can improve survival rates for African American patients suffering from this disease.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for African American patients with liver cancer.
How similar studies have gone: Previous research has shown promise in addressing health disparities in cancer treatment, indicating that this approach could yield significant advancements.
Where this research is happening
-
Glax, LLC
Wilmington, United States Active
Researchers
- Principal investigator: Srivastava, Rakesh K. — Glax, LLC
- Study coordinator: Srivastava, Rakesh K.
Related research
Other NIH-funded projects on the same topics.
-
Glutamine and macrophage behavior in liver cancer
A funded project at a medical university aims to understand how the liver’s immune cells interact with a specific type of liver cancer by looking at metabolism, especially glutamine and ammonia.
-
Adding PSMA PET/CT imaging to liver cancer care for veterans
This project tests a new PET imaging approach to help diagnose and guide treatment for liver cancer in veterans.
-
Blood markers to catch early liver cancer in Hispanic people with hepatitis B
This project will see if a blood test can find liver cancer earlier in Hispanic people who have chronic hepatitis B.
-
Early blood markers to find hepatitis B–related liver cancer in Hispanics
This project will use immune-related blood markers to find liver cancer earlier in people with chronic hepatitis B, focusing on Hispanic adults.
-
Towards a blood-based test using nanophotonic exosomes to screen and diagnose liver cancer
A new blood test using tiny particles shed by liver cancer cells aims to screen for hepatocellular carcinoma earlier and more accurately.
-
Metabolic imaging to guide targeted therapy for liver cancer
A clinician-scientist at UPenn is pursuing training to use metabolic imaging to tailor therapy for hepatocellular carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.